sb 216763 has been researched along with Carcinoma, Anaplastic in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bar-Yehuda, S; Barer, F; Erlanger, A; Fishman, P; Madi, L; Ochaion, A; Ohana, G | 1 |
1 other study(ies) available for sb 216763 and Carcinoma, Anaplastic
Article | Year |
---|---|
An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B.
Topics: Adenosine; Animals; beta Catenin; Carcinoma; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Cyclin D1; Cytoskeletal Proteins; Down-Regulation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Growth Inhibitors; Humans; Indoles; Lithium; Maleimides; Mice; Mice, Nude; NF-kappa B; Proto-Oncogene Proteins c-myc; Purinergic P1 Receptor Agonists; Pyridines; Trans-Activators | 2004 |